In this episode of SciBud, your go-to source for the latest in science news, we dive into a groundbreaking study examining the survival of retinal ganglion cells (RGCs) in the context of glaucoma, a leading cause of irreversible blindness. Join Maple as we explore how researchers are tackling the challenge of low survival rates for transplanted RGCs by employing slow-release neuroprotective factors, specifically brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF). The findings are remarkable, showing a staggering 15-fold increase in human RGC survival after transplantation, offering hope for new therapeutic strategies to restore vision lost to neurodegeneration. We also delve into the study’s implications for bioimaging and the broader significance for future treatments of optic neuropathies. Tune in and discover how advancements in understanding RGC survival could pave the way for innovative recovery solutions, while reflecting on the complexities that still lie ahead in the field of retinal research. Stay curious, and let’s uncover the wonders of science together! Link to episode page with article citation: www.scibud.media/podcast/season/2025/episode/173